Adage Capital Partners
RLMD icon

Adage Capital Partners’s Relmada Therapeutics RLMD Stock Holding History

Adage Capital Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.2M Buy
4,763,158
+493,158
+12% +$2.33M 0.05% 346
2025
Q4 		$20.6M Buy
+4,270,000
New +$14.3M 0.03% 472

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Adage Capital Partners's RLMD Position: Q1 2026 in Review

Adage Capital Partners increased its Relmada Therapeutics (RLMD) stake by 12% in Q1 2026, buying an estimated $2.33M and bringing the position to 4,763,158 shares worth $33.2M. The position accounts for 0.05% of the portfolio, ranked #346.

Adage Capital Partners first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Adage Capital Partners held 4,763,158 shares of Relmada Therapeutics worth $33.2M as of Q1 2026.
  • Adage Capital Partners bought 493,158 Relmada Therapeutics shares in Q1 2026, an estimated $2.33M.
  • Relmada Therapeutics made up 0.05% of Adage Capital Partners's portfolio in Q1 2026, its #346 holding.
  • Adage Capital Partners first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.